A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

A Phase 2, multicenter, adaptive 2-part clinical trial designed to evaluate the safety and efficacy of ADX-629 alone and in combination with standard-of-care in adults with atopic dermatitis.

Inclusion Criteria:Adults ≥18 years of ageHistory of atopic dermatitis, according to American Academy of Dermatology criteria, that has been present for at least 6 monthsMild, moderate, or severe atopic dermatitis, defined as an IGA score of ≥2 at BaselineNot pregnant, breastfeeding, or lactating and agree to use a highly effective method of acceptable contraceptive for the trial duration, if applicableExclusion Criteria:Presence of clinically significant kidney disease or an estimated gloverular filtration rate (eGFR) of less than or equal to 45 milliliters/min/1.73 m2 during screeningHistory of any unstable chronic diseases/conditions, clinically significant abnormalities, or findings, that in the opinion of the Investigator, could compromise subject safety or affect the conduct of the trial